

...continued from previous page.

ASBA#

Simple, Safe,  
Smart way of Application!!!

# Applications supported by blocked amount (ASBA) is a better way of applying to issues by simply blocking the fund in the bank account. For further details, check section on ASBA.

Mandatory in public issues. No cheque will be accepted.

UPI

UNITED PAYMENTS INTERFACE

UPI-Now available in ASBA for Retail Individual Investors and Non - Institutional Investor applying for amount upto ₹ 5,00,000/-, applying through Registered Brokers, DP's and RTA's. UPI Bidder also have the option to submit the application directly to the ASBA Bank (SCSBs) or to use the facility of linked online trading, demat and bank account. Investors are required to ensure that the bank account used for bidding is linked to their PAN. Bidders must ensure that their PAN is linked with Aadhaar and are in compliance with CDBT notification dated February 13, 2020, issued by the Central Board of Direct Taxes and the subsequent press releases, including press releases dated June 25, 2021 and September 17, 2021 and CDBT circular no.7 of 2022, dated March 30, 2022 read with press release dated March 28, 2023 and any subsequent press releases in this regard.

ASBA has to be availed by all the investors except anchor investors. UPI may be availed by UPI Bidders. For details on the ASBA and UPI process, please refer to the details given in ASBA form and abridged prospectus and also please refer to the section "Offer Procedure" on page 514 of the RHP. The process is also available on the website of Association of Investment Bankers of India ("AIBI") and Stock Exchanges and in the General Information Document. ASBA bid-cum-application forms can be downloaded from the websites of the Stock Exchanges and can be obtained from the list of banks that is displayed on the website of SEBI at [www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmid=35](http://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmid=35) and <https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmid=43>, respectively as updated from time to time. For the list of UPI apps and banks live on IPO, please refer to the link: [www.sebi.gov.in](http://www.sebi.gov.in). RIBs Bidding using the UPI mechanism may apply through the SCSBs and mobile applications whose names appear on the website of SEBI, as updated from time to time. HDFC Bank Limited and Axis Bank Limited have been appointed as Sponsor Banks for the issue, in accordance with the requirements of the SEBI Circular dated November 1, 2018 as amended. For issue related queries, please contact the BRLMs on their respective email IDs as mentioned below. For UPI related queries, investors can contact NPCI at the toll free number: 18001201740 and mail ID: ipo.upi@npci.org.in.

THE EQUITY SHARES OF OUR COMPANY WILL GET LISTED ON MAIN BOARD PLATFORM OF BSE AND NSE

In case of any revision in the Price Band, the Bid/ Offer Period shall be extended for at least three additional Working Days after such revision of the Price Band, subject to the total Bid/Offer Period not exceeding 10 Working Days. In cases of force majeure, banking strike or similar circumstances, our Company in consultation with the BRLMs, for reasons to be recorded in writing, extend the Bid / Offer Period for a minimum of three Working Days, subject to the Bid/ Offer Period not exceeding 10 Working Days. Any revision in the Price Band, and the revised Bid/ Offer Period, if applicable, shall be widely disseminated by notification to the Stock Exchanges by issuing a press release and also by indicating the change on the websites of the BRLMs and at the terminals of the Members of the Syndicate and by intimation to Designated Intermediaries and Sponsor Banks, as required under the SEBI ICDR Regulations.

The Offer is being made through the Book Building Process, in terms of Rule 19(2)(b) of the Securities Contracts (Regulation) Rules, 1957, as amended ("SCRR") read with Regulation 31 of the SEBI ICDR Regulations and in compliance with Regulation 6(2) of the SEBI ICDR Regulations, wherein not less than 75% of the Net Offer shall be allocated on a proportionate basis to the Qualified Institutional Buyers ("QIBs") ("QIB Portion"), provided that our Company in consultation with the BRLMs, may allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations ("Anchor Investor Portion"), of which at least one-third shall be reserved for domestic Mutual Funds, subject to valid Bids being received from domestic Mutual Funds at or above the Anchor Investor Allocation Price. In the event of under-subscription, or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the Net QIB Portion (excluding the Anchor Investor Portion) ("Net QIB Portion"). Further, 5% of the Net QIB Portion shall be available for allocation on a proportionate basis only to Mutual Funds, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIBs other than Anchor Investors, including Mutual Funds, subject to valid Bids being received at or above the Offer Price. Further, not more than 15% of the Net Offer shall be available for allocation on a proportionate basis to Non-Institutional Investors of which (a) one-third of such portion shall be reserved for applicants with application size of more than ₹200,000 and up to ₹1,000,000; and (b) two-third of such portion shall be reserved for applicants with application size of more than ₹1,000,000, provided that the unsubscribed portion in either of such sub-categories may be allocated to applicants in the other sub-category of Non-Institutional Bidders and not more than 10% of the Net Offer shall be available for allocation to Retail Individual Bidders in accordance with the SEBI ICDR Regulations, subject to valid Bids being received at or above the Offer Price. Further, Equity Shares will be allotted on a proportionate basis to Eligible Employees applying under the Employee Reservation Portion, subject to valid Bids received from them at or above the Offer Price (net of Employee Discount, if any). All potential Bidders (except Anchor Investors) are required to mandatorily utilise the Application Supported by Blocked Amount ("ASBA") process providing details of their respective ASBA accounts, and UPI ID (in case of UPI Bidders) if applicable, in which the corresponding Bid Amounts will be blocked by the SCSBs or by the Sponsor Bank(s) under the UPI Mechanism, as applicable, to the extent of the respective Bid Amounts. Anchor Investors are not permitted to participate in the Offer through the ASBA process. For details, see "Offer Procedure" beginning on page 514 of the RHP.

Bidders/Applicants should ensure that DP ID, PAN, Client ID and UPI ID (for UPI Bidders bidding through the UPI Mechanism) are correctly filled in the Bid cum Application Form. The DP ID, PAN and Client ID provided in the Bid cum Application Form should match with the DP ID, PAN, Client ID available in the Depository database, otherwise, the Bid cum Application Form is liable to be rejected. Bidders/ Applicants should ensure that the beneficiary account provided in the Bid cum Application Form is active. Bidders/Applicants should note that on the basis of the PAN, DP ID, Client ID and UPI ID (for UPI Bidders bidding through the UPI Mechanism) as provided in the Bid cum Application Form, the Bidder/Applicant may be deemed to have authorised the Depositories to provide to the Registrar to the Issue, any requested Demographic Details of the Bidder/Applicant as available on the records of the depositories. These Demographic Details may be used, among other things, for giving Allotment Advice or unblocking of ASBA Account or for other correspondence(s) related to the Issue. Bidders/Applicants are advised to update any changes to their Demographic Details as available in the records of the Depository Participant to ensure accuracy of records. Any delay resulting from failure to update the Demographic Details would be at the Bidders/Applicants' sole risk. Investors must ensure that their PAN is linked with Aadhaar and are in compliance with CDBT notification dated February

13, 2020 and press release dated June 25, 2021, read with press release dated September 17, 2021 and CDBT circular no.7 of 2022, dated March 30, 2022 read with press release dated March 28, 2023 and any subsequent press releases in this regard.

**Contents of the Memorandum of Association of our Company as regards its objects:** For information on the main objects of our Company, please see the section "History and Certain Corporate Matters" on page 209 of the RHP. The Memorandum of Association of our Company is a material document for inspection in relation to the Issue. For further details, please see the section titled "Material Contracts and Documents for Inspection" on page 555 of the RHP.

**Liability of the members of our Company:** Limited by shares

**Amount of share capital of our Company and Capital structure:** As on the date of the RHP, the authorised share capital of the Company is ₹ 9,743,500,000 divided into 74,570,000 Equity Shares of face value ₹ 10 each and 565,847,000 Series A1 CCPS, 193,564,100 Series A2 CCPS, 3,996,900 Series A3 CCPS, 36,372,000 Series A4 CCPS and 100,000,000 Series A5 CCPS, of face value of ₹ 10 each. The issued, subscribed and paid-up share capital of the Company is ₹ 355,431,980 divided into 35,543,198 Equity Shares of face value ₹ 10 each. For details, please see the section titled "Capital Structure" on page 93 of the RHP.

**Names of signatories to the Memorandum of Association of our Company and the number of Equity Shares subscribed by them:** The initial signatories to the Memorandum of Association of our Company are Prabhakar Agrawal and Prem Sethi. For details of the share capital history and capital structure of our Company, please see the section titled "Capital Structure" on page 93 of the RHP.

**Listing:** The Equity Shares offered through this Red Herring Prospectus are proposed to be listed on BSE and NSE. Our Company has received in-principle approvals from BSE and NSE for listing of the Equity Shares pursuant to their letters each dated November 8, 2023. For the purposes of this Offer, BSE shall be the Designated Stock Exchange. A signed copy of this Red Herring Prospectus and the Prospectus shall be filed with the RoC in accordance with Sections 26(4) and 32 of the Companies Act, 2013. For details of the material contracts and documents available for inspection from the date of this Red Herring Prospectus up to the Bid/Offer Closing Date, see "Material Contracts and Documents for Inspection" on page 555 of the RHP.

**Disclaimer Clause of the Securities and Exchange Board of India ("SEBI"):** SEBI only gives its observations on the offer documents and this does not constitute approval of either the Offer or the specified securities or the offer document. The investors are advised to refer to page 490 of the RHP for the full text of the disclaimer clause of SEBI.

**Disclaimer Clause of NSE:** It is to be distinctly understood that the permission given by NSE should not in any way be deemed or construed that the Offer Document has been cleared or approved by NSE nor does it certify the correctness or completeness of any of the contents of the Offer Document. The investors are advised to refer to page 492 of the RHP for the full text of the disclaimer clause of NSE.

**Disclaimer Clause of BSE (Designated Stock Exchange):** It is to be distinctly understood that the permission given by BSE Limited should not in any way be deemed or construed that the Red Herring Prospectus has been cleared or approved by BSE Limited nor does it certify the correctness or completeness of any of the contents of the Red Herring Prospectus. The investors are advised to refer to page 492 of the Red Herring Prospectus for the full text of the disclaimer clause of BSE Limited.

**General Risk:** Investments in equity and equity-related securities involve a degree of risk and investors should not invest any funds in this Offer unless they can afford to take the risk of losing their entire investment. Investors are advised to read the risk factors carefully before taking an investment decision in this Offer. For taking an investment decision, investors must rely on their own examination of the Issuer and this Offer, including the risks involved. The Equity Shares have not been recommended or approved by the Securities and Exchange Board of India ("SEBI"), nor does SEBI guarantee the accuracy or adequacy of the contents of this Red Herring Prospectus. Specific attention of the investors is invited to "Risk Factors" on page 39 of the RHP.

| BOOK RUNNING LEAD MANAGERS   |  |   |   |  | REGISTRAR TO THE OFFER  | COMPANY SECRETARY AND COMPLIANCE OFFICER  |
|--|--|---|---|--|---|---|
|  |  |   |   |  |   | <b>Jayant Prakash</b><br>Vice President - General Counsel,<br>Company Secretary and Compliance Officer.<br>Tel: +91 22-69019100<br>Email: <a href="mailto:jayant.prakash@enterohealthcare.com">jayant.prakash@enterohealthcare.com</a>  |
| <b>ICICI Securities Limited</b><br>ICICI Venture House,<br>Appasaheb Marathe Marg,<br>Prabhadevi, Mumbai - 400 025<br>Tel: +91 22 6807 7100<br>Email: <a href="mailto:entero ipo@icicisecurities.com">entero ipo@icicisecurities.com</a><br>Investor grievance email:<br><a href="mailto:customer.care@icicisecurities.com">customer.care@icicisecurities.com</a><br>Website: <a href="http://www.icicisecurities.com">www.icicisecurities.com</a><br>Contact person: Shekher Asnani / Gaurav Mittal<br>SEBI registration no: INM000011179 | <b>DAM Capital Advisors Limited</b><br>One BKC, Tower C, 15th Floor, Unit No. 1511,<br>Bandra Kurla Complex, Bandra (East),<br>Mumbai - 400 051, Maharashtra, India<br>Tel: +91 22 4202 2500<br>E-mail: <a href="mailto:entero ipo@damcapital.in">entero ipo@damcapital.in</a><br>Investor grievance e-mail:<br><a href="mailto:investor.grievance@damcapital.in">investor.grievance@damcapital.in</a><br>Website: <a href="http://www.damcapital.in">www.damcapital.in</a><br>Contact Person: Arpi Chheda<br>SEBI Registration: MB/INM000011336 | <b>Jefferies India Private Limited</b><br>16th Floor, Express Towers,<br>Nariman Point, Mumbai 400 021<br>Maharashtra, India<br>Tel: +91 22 4356 6000<br>E-mail: <a href="mailto:Enterohealthcare.IPO@jefferies.com">Enterohealthcare.IPO@jefferies.com</a><br>Investor grievance e-mail:<br><a href="mailto:ipj.grievance@jefferies.com">ipj.grievance@jefferies.com</a><br>Website: <a href="http://www.jefferies.com">www.jefferies.com</a><br>Contact Person: Suhani Bhareja<br>SEBI Registration: INM000011443 | <b>JM Financial Limited</b><br>7th Floor, Chenergy<br>Appasaheb Marathe Marg,<br>Prabhadevi, Mumbai 400 025<br>Maharashtra, India<br>Tel: +91 22 6630 3030<br>E-mail: <a href="mailto:entero ipo@jmfml.com">entero ipo@jmfml.com</a><br>Investor Grievance E-Mail:<br><a href="mailto:grievance.lbd@jmfml.com">grievance.lbd@jmfml.com</a><br>Website: <a href="http://www.jmfml.com">www.jmfml.com</a><br>Contact person: Prachee Dhuri<br>SEBI Registration No.: INM000010361 | <b>SBI Capital Markets Limited</b><br>Unit No. 1501, 15th floor, A & B Wing,<br>Parinee Crescendo Building, Plot C-38,<br>G Block, Bandra Kurla Complex, Bandra (East),<br>Mumbai-400 051, Maharashtra.<br>Tel: +91 22 4006 9807<br>E-mail: <a href="mailto:entero ipo@sbicaps.com">entero ipo@sbicaps.com</a><br>Investor Grievance E-Mail:<br><a href="mailto:investor.relations@sbicaps.com">investor.relations@sbicaps.com</a><br>Website: <a href="http://www.sbicaps.com">www.sbicaps.com</a><br>Contact person: Aditya Deshpande<br>SEBI Registration No.: INM000003531 | <b>Link Intime India Private Limited</b><br>C-101, 1st floor, 247 Park, Lal Bahadur<br>Shastri Marg, Vikhroli (West)<br>Mumbai 400 083, Maharashtra, India<br>Tel: +91 8108114949<br>E-mail: <a href="mailto:enterohealthcare.ipo@linkintime.co.in">enterohealthcare.ipo@linkintime.co.in</a><br>Investor grievance e-mail:<br><a href="mailto:enterohealthcare.ipo@linkintime.co.in">enterohealthcare.ipo@linkintime.co.in</a><br>Website: <a href="http://www.linkintime.co.in">www.linkintime.co.in</a><br>Contact person: Shanti Gopalkrishnan<br>SEBI Registration No.: INR000004058 | Investors may contact the Company Secretary and Compliance Officer or the Registrar to the Issue in case of any pre-issue or post-issue related grievances including non-receipt of letters of Allotment, non-credit of Allotted Equity Shares in the respective beneficiary account, non-receipt of refund orders or non-receipt of funds by electronic mode, etc. For all issue related queries and for redressal of complaints, investors may also write to the BRLMs. |

**AVAILABILITY OF THE RHP:** Investors are advised to refer to the RHP and the section titled "Risk Factors" on page 39 of the RHP, before applying in the Issue. A copy of the RHP shall be available on website of SEBI at [www.sebi.gov.in](http://www.sebi.gov.in), websites of the Stock Exchanges i.e. BSE Limited and National Stock Exchange of India Limited at [www.bseindia.com](http://www.bseindia.com) and [www.nseindia.com](http://www.nseindia.com), respectively, and the website of the Company at [www.enterohealthcare.com](http://www.enterohealthcare.com) and the websites of the BRLMs, i.e. ICICI Securities Limited, DAM Capital Advisors Limited, Jefferies India Private Limited, JM Financial Limited and SBI Capital Markets Limited at [www.icicisecurities.com](http://www.icicisecurities.com), [www.damcapital.in](http://www.damcapital.in), [www.jefferies.com](http://www.jefferies.com), [www.jmfml.com](http://www.jmfml.com) and [www.sbicaps.com](http://www.sbicaps.com), respectively.

**AVAILABILITY OF BID CUM APPLICATION FORMS:** Bid cum Application Forms can be obtained from the Registered Office of ENTERO HEALTHCARE SOLUTIONS LIMITED, Tel: 0129-4877300; BRLMs: ICICI Securities Limited, Tel: +91 22 6807 7100; DAM Capital Advisors Limited, Tel: +91 22 4202 2500; Jefferies India Private Limited, Tel: +91 22 4356 6000; JM Financial Limited, Tel: +91 22 6630 3030 and SBI Capital Markets Limited, Tel: +91 22 4006 9807; **Syndicate Members:** SBICAP Securities Limited, Tel: 91 22 69316204; Investec Capital Services (India) Private Limited, Tel: +91 22 6849 7400; Sharekhan Limited, Tel: +91 22 6750 2000; JM Financial Services Limited, Tel: +91 22 6136 3400 and at the select locations of the Sub-syndicate Members (as given below), SCSBs, Registered Brokers, RTAs and CDPs participating in the Issue. ASBA Forms will also be available on the websites of BSE and NSE and the Designated Branches of SCSBs, the list of which is available at websites of the Stock Exchanges and SEBI.

**Sub-Syndicate Members:** Almondz Global Securities Limited, Anand Rathi Share & Stock Brokers Limited, Axis Capital Limited, Centrum Broking Limited, Choice Equity Broking Private Limited, DB(International) Stock Brokers Limited, Eureka Stock & Share Broking Services Limited, Globe Capital Markets Limited, HDFC Securities Limited, IDBI Capital Markets & Securities Limited, JM Financial Services Limited, Jobanputra Fiscal Services Private Limited, Keynote Capitals Limited, KJMC Capital Market Services Limited, Kotak Securities Limited, LKP Securities Limited, Inventure Growth & Securities Limited, Motilal Oswal Financial Services Limited, Nirmal Bang Securities Private Limited, NuVama Wealth and Investment Limited (Edelweiss Broking Limited), Prabhudas Liladhar Private Limited, Pravin Rathi Share and Stock Brokers Limited, Religare Broking Limited, RR Equity Brokers Private Limited, SMC Global Securities Limited, Standard Chartered Securities Limited, Systematix Shares and Stocks (India) Limited, Trade Bulls Securities (P) Limited and Yes Securities (India) Limited.

**Escrow Collection Bank and Refund Bank:** Axis Bank Limited

**Public Issue Account Bank:** HDFC Bank Limited • **Sponsor Banks:** HDFC Bank Limited and Axis Bank Limited.

All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the RHP.

For ENTERO HEALTHCARE SOLUTIONS LIMITED

On behalf of the Board of Directors

Sd/-

Jayant Prakash

Vice President - General Counsel, Company Secretary and Compliance Officer

Place: Mumbai

Date: February 5, 2024

ENTERO HEALTHCARE SOLUTIONS LIMITED is proposing, subject to applicable statutory and regulatory requirements, the receipt of requisite approvals, market conditions and other considerations, to undertake an initial public offering of its Equity Shares and has filed the RHP dated February 5, 2024 with the RoC and thereafter with the Stock Exchanges. The RHP is available on the website of SEBI at [www.sebi.gov.in](http://www.sebi.gov.in), websites of the Stock Exchanges i.e. BSE Limited and National Stock Exchange of India Limited at [www.bseindia.com](http://www.bseindia.com) and [www.nseindia.com](http://www.nseindia.com), respectively, the website of the Company at [www.enterohealthcare.com](http://www.enterohealthcare.com) and the websites of the BRLMs, i.e. ICICI Securities Limited, DAM Capital Advisors Limited, Jefferies India Private Limited, JM Financial Limited and SBI Capital Markets Limited at [www.icicisecurities.com](http://www.icicisecurities.com), [www.damcapital.in](http://www.damcapital.in), [www.jefferies.com](http://www.jefferies.com), [www.jmfml.com](http://www.jmfml.com) and [www.sbicaps.com](http://www.sbicaps.com), respectively. Any potential investors should note that investment in equity shares involves a high degree of risk and for details relating to such risk, please see the section titled "Risk Factors" on page 39 of the RHP. Potential investors should not rely on the DRHP filed with SEBI for making any investment decision.

The Equity Shares offered in the Offer have not been and will not be registered under the U.S. Securities Act of 1933, as amended ("U.S. Securities Act"), or any state law of the United States and, unless so registered, may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable state securities laws. Accordingly, the Equity Shares are being offered and sold (i) within the United States only to persons reasonably believed to be "qualified institutional buyers" (as defined in Rule 144A under the U.S. Securities Act) under Section 4(a) of the U.S. Securities Act, and (ii) outside the United States in "offshore transactions" as defined in and in compliance with Regulation S under the U.S. Securities Act and the applicable laws of the jurisdiction where those offers and sales are made. There will be no public offering of the Equity Shares in the United States.

Adfactors 562

CLASSIFIED CENTRES IN MUMBAI

Bejay Ads,  
Opera House  
Phone : 23692926 / 56051035.

Color Spot,  
Byculla (E),  
Phone : 23748048 / 23714748.

FCA Communications,  
Nariman Point,  
Phone : 40020550 / 51.

Fulrani Advtg. & Mktg.  
Antop Hill  
Phone: 24159061  
Mobile: 9769238274 / 9969408835

Ganesh Advertising,  
Abdul Rahman Street,  
Phone : 2342 9163 / 2341 4596.

J.K. Advertisers,  
Hornimal Circle, Fort,  
Phone : 22663742.

Mani's Agencies,  
Opp.G.P.O., Fort,  
Phone : 2263 00232.  
Mobile : 9892091257.

Maniyot Ads,  
Currey Road (E)  
Phone : 24700338.  
Mobile : 9820460262.


OM Sai Ram Advtg,  
Currey Road  
Mobile: 9967375573

Pinto Advertising,  
Mazagon,  
Phone : 23701070.  
Mobile : 9869040181.

Premier Advertisers  
Mumbai Central  
Mobile: 9819891116

Sarian Advertising,  
Tardeo,  
Phone : 66626983.  
[financialexp.epaprr.in](mailto:financialexp.epaprr.in)

| RESPONSIVE INDUSTRIES LIMITED  |                           |                           |                           |                           |                           |                                       |
|--|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------------------|
| CIN No. : L65100MH1982PLC027797  |                           |                           |                           |                           |                           |                                       |
| Regd. Office : Village Belgaon, Mahagaon Road, Boisar - East, Dist. Palghar - 401 501  |                           |                           |                           |                           |                           |                                       |
| Email ID: <a href="mailto:investor@responsiveindustries.com">investor@responsiveindustries.com</a> ; Website: <a href="http://www.responsiveindustries.com">www.responsiveindustries.com</a> ; Tel No. : 022-66562821; Fax No. : 022-66562798  |                           |                           |                           |                           |                           |                                       |
| EXTRACT OF THE UNAUDITED FINANCIAL RESULTS FOR THE THIRD QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2023   |                           |                           |                           |                           |                           |                                       |
| Particulars  | (Rs in lakhs)             |                           |                           |                           |                           |                                       |
|  | Standalone                |                           |                           |                           |                           | Year Ended<br>31.03.2023<br>(Audited) |
|  | 31.12.2023<br>(Unaudited) | 30.09.2023<br>(Unaudited) | 31.12.2022<br>(Unaudited) | 31.12.2022<br>(Unaudited) | 31.12.2022<br>(Unaudited) |                                       |
| Total Income from operations   | 13,983.51                 | 17,389.44                 | 14,859.50                 | 51,044.31                 | 50,983.03                 | 68,253.77                             |
| Net Profit / (Loss) for the period (before Tax, Exceptional and/ or Extraordinary items)   | 1,177.13                  | 986.64                    | 422.69                    | 2,998.17                  | 1,315.66                  | 1,685.48                              |
| Net Profit / (Loss) for the period after tax (after Exceptional and/ or Extraordinary items)   | 936.34                    | 737.65                    | 309.09                    | 2,313.08                  | 1,004.90                  | 1,283.89                              |
| Total Comprehensive Income for the period (Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax))   | 936.34                    | 737.65                    | 309.09                    | 2,313.08                  | 1,004.90                  | 1,321.51                              |
| Equity Share Capital   | 2,666.09                  | 2,666.09                  | 2,666.09                  | 2,666.09                  | 2,666.09                  | 2,666.09                              |
| Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year.   | -                         | -                         | -                         | -                         | -                         | 86,777.88                             |
| Earnings per share (before extraordinary items) of Re. 1/- each (not annualised):  |                           |                           |                           |                           |                           |                                       |
| (a) Basic  | 0.35                      | 0.28                      | 0.12                      | 0.87                      | 0.38                      | 0.48                                  |
| (b) Diluted  | 0.35                      | 0.28                      | 0.12                      | 0.87                      | 0.38                      | 0.48                                  |
| Particulars  | (Rs. in Lakhs)            |                           |                           |                           |                           |                                       |
|  | Consolidated              |                           |                           |                           |                           | Year Ended<br>31.03.2023<br>(Audited) |
|  | 31.12.2023<br>(Unaudited) | 30.09.2023<br>(Unaudited) | 31.12.2022<br>(Unaudited) | 31.12.2022<br>(Unaudited) | 31.12.2022<br>(Unaudited) |                                       |
| Total Income from operations   | 26,874.84                 | 27,380.27                 | 26,719.24                 | 80,820.06                 | 74,998.08                 | 98,965.73                             |
| Net Profit / (Loss) for the period (before Tax, Exceptional and/ or Extraordinary items)   | 4,711.93                  | 4,316.40                  | 1,795.56                  | 12,224.64                 | 476.29                    | 2,838.67                              |
| Net Profit / (Loss) for the period after tax (after Exceptional and/ or Extraordinary items)   | 4,471.14                  | 4,067.41                  | 1,681.96                  | 11,539.55                 | 165.53                    | 2,439.25                              |
| Total Comprehensive Income for the period (Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax))   | 4,586.09                  | 4,424.90                  | 2,007.07                  | 12,016.23                 | 1,465.13                  | 3,807.39                              |
| Equity Share Capital   | 2,666.09                  | 2,666.09                  | 2,666.09                  | 2,666.09                  | 2,666.09                  | 2,666.09                              |
| Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year.   | -                         | -                         | -                         | -                         | -                         | 97,232.92                             |
| Earnings per share (before extraordinary items) of Re. 1/- each (not annualised):  |                           |                           |                           |                           |                           |                                       |
| (a) Basic  | 1.68                      | 1.53                      | 0.63                      | 4.33                      | 0.06                      | 0.91                                  |
| (b) Diluted  | 1.68                      | 1.53                      | 0.63                      | 4.33                      | 0.06                      | 0.91                                  |
| <b>Note :</b> The above is an extract of the detailed format of Unaudited Standalone and Consolidated Financial Results for the third quarter and nine months ended December 31, 2023, filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of Unaudited Standalone and Consolidated Financial Results for the third quarter and nine months ended December 31, 2023 is available on the Stock Exchanges website at <a href="http://www.bseindia.com">www.bseindia.com</a> and on the Company's website at <a href="http://www.responsiveindustries.com">www.responsiveindustries.com</a> . |                           |                           |                           |                           |                           |                                       |
| <b>For Responsive Industries Limited</b><br>Mehul Vala<br>Whole-Time Director & CEO<br>DIN No. : 08361696  |                           |                           |                           |                           |                           |                                       |
| <b>Place : Mumbai</b><br><b>Date : February 05, 2024</b>   |                           |                           |                           |                           |                           |                                       |


**SANJIVANI**  
 PARANTERAL LIMITED  
 25 years of Care & Excellence

# SANJIVANI PARANTERAL LIMITED

Corporate Identity Number: L24300MH1994PLC081752

Registered Office: 205, P. N. KOTHARI INDL. ESTATE, L.B.S. MARG, BHANDUP (W), MUMBAI - 400 078.

Tel.: 022 20812600 | Email ID: info@sanjivani.co.in

## STANDALONE UN-AUDITED STATEMENT OF FINANCIAL RESULTS FOR THE QUARTER ENDED 31<sup>ST</sup> DECEMBER' 2023

(₹ In Lacs (Except earning per share))

| Sr. No.   | Particulars   | Quarter ended on |                |               | Nine Months ended on |                | Previous Year  |
|-----------|---|------------------|----------------|---------------|----------------------|----------------|----------------|
|           |   | 31-12-2023       | 30-09-2023     | 31-12-2022    | 31-12-2023           | 31-12-2022     | Year ended on  |
|           |   | Unaudited        | Unaudited      | Unaudited     | Unaudited            | Unaudited      | Audited        |
| <b>1</b>  | <b>Revenue from operations</b>  |                  |                |               |                      |                |                |
| a)        | Revenue from operations   | 1496.28          | 1400.26        | 912.15        | 4154.64              | 2736.95        | 3061.26        |
| b)        | Other income  | 25.43            | 15.01          | 31.04         | 46.47                | 59.39          | 24.33          |
|           | <b>Total revenue</b>  | <b>1521.71</b>   | <b>1415.27</b> | <b>943.19</b> | <b>4201.11</b>       | <b>2796.34</b> | <b>3085.59</b> |
| <b>2</b>  | <b>Expenses</b>   |                  |                |               |                      |                |                |
| a)        | Cost of material consumed   | 1145.77          | 1036.56        | 567.68        | 2689.02              | 1485.08        | 1265.77        |
| b)        | Changes in inventories of finished goods, work-in-progress and stock-in-trade       | -348.10          | -140.09        | 3.55          | -335.64              | 21.49          | (35.34)        |
| c)        | Employee benefits expenses  | 119.72           | 87.39          | 59.56         | 296.34               | 193.92         | 308.70         |
| d)        | Finance costs   | 7.65             | 4.59           | 5.35          | 16.51                | 19.89          | 21.32          |
| e)        | Depreciation and amortization expenses  | 23.51            | 23.19          | 22.56         | 69.57                | 66.00          | 87.74          |
| f)        | Other expenses  | 383.04           | 205.02         | 189.18        | 896.59               | 615.27         | 949.54         |
|           | <b>Total expenses</b>   | <b>1331.59</b>   | <b>1216.66</b> | <b>847.88</b> | <b>3632.39</b>       | <b>2401.65</b> | <b>2597.73</b> |
| <b>3</b>  | <b>Profit/ (Loss) before tax (1-2)</b>  | <b>190.12</b>    | <b>198.61</b>  | <b>95.31</b>  | <b>568.72</b>        | <b>394.69</b>  | <b>487.86</b>  |
| <b>4</b>  | <b>Tax expenses</b>   |                  |                |               |                      |                |                |
| -         | Current   | 25.00            | 28.00          | 0.00          | 78.00                | 50.08          | 0.00           |
| -         | Deferred  | 0.00             | 0.00           | 0.00          | 0.00                 | -6.88          | 3.22           |
| <b>5</b>  | <b>Net Profit / (Loss) for the period (9-10)</b>                                    | <b>165.12</b>    | <b>170.61</b>  | <b>95.31</b>  | <b>490.72</b>        | <b>351.49</b>  | <b>484.64</b>  |
| <b>6</b>  | <b>Other comprehensive income (Net of taxes)</b>                                    | <b>0.00</b>      | <b>0.00</b>    | <b>0.00</b>   | <b>0.00</b>          | <b>0.00</b>    | <b>0.00</b>    |
| <b>7</b>  | <b>Total Comprehensive Income For The Period</b>                                    | <b>165.12</b>    | <b>170.61</b>  | <b>95.31</b>  | <b>490.72</b>        | <b>351.49</b>  | <b>484.64</b>  |
| <b>8</b>  | <b>Comprehensive Income For The Period Attributable To The Owners Of The Parent</b> | <b>165.12</b>    | <b>170.61</b>  | <b>95.31</b>  | <b>490.72</b>        | <b>351.49</b>  | <b>484.64</b>  |
| <b>9</b>  | <b>Paid-up Equity Share Capital, (Face Value ₹10/- Each)</b>                        | <b>999.83</b>    | <b>999.83</b>  | <b>999.83</b> | <b>999.83</b>        | <b>999.83</b>  | <b>999.83</b>  |
| <b>10</b> | <b>Earning Per Share (IN ₹)</b>   |                  |                |               |                      |                |                |
| a)        | Basic Earnings (Loss) Per Share   | 1.65             | 1.71           | 0.95          | 4.91                 | 3.52           | 4.85           |
| b)        | Diluted Earnings (Loss) Per Share   | 1.65             | 1.71           | 0.95          | 4.91                 | 3.52           | 4.85           |

### Notes:

- The Statement of financials results have been prepared in accordance with the recognition and measurement principles laid down in IND AS 34 Interim Financial Reporting prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder.
- The above statement of Financial Results, as reviewed by Audit Committee, were approved and taken on record by the Board of Directors in their meeting held on 5<sup>th</sup> February' 2024
- Previous Year's / Period's figures have been regrouped or reclassified wherever necessary.
- The Statutory Auditors have carried out a 'Limited Review of the Company's results in terms of Clause 41 of the Listing Agreement with Stock Exchange.
- Nil investors complaints were received during the quarter. There was no complaint outstanding at the beginning or at the end of the quarter.
- Company has only one business segment of pharmaceutical in terms of the requirement as per IND AS 108 on "Operating Segment Reporting".

For Sanjivani Paranteral Ltd

Sd/-

Ashwani Khemka

Managing Director

DIN: 00337118

Place : Mumbai

Date : 5<sup>th</sup> February 2024